Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG

Cheng Hsun Ho, Hung Wen Tsai, Chen Yeh Lee, Li Juan Huang, Rong Nan Chien, I. Chin Wu, Yen Cheng Chiu, Wen Chun Liu, Pin Nan Cheng, Ting Tsung Chang, Shu Hui Chen

研究成果: Article

1 引文 (Scopus)

摘要

Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed. After a screening of 1,085 patients, 132 eligible HBV e antigen (HBeAg)-positive and 101 HBeAg-negative patients with anti-HBV nucleos(t)ide analogue monotherapy were enrolled with on-treatment follow-ups for at least one year. IgG1 N-glycome was profiled using mass spectrometry and evaluated for its relevance in treatment responses. The results indicated that a high level of serum fucosyl-agalactosyl IgG1 (IgG1-G0F) at baseline was associated with the severity of liver inflammation and damage but advanced treatment responses, including HBV DNA loss, HBeAg seroconversion, a reduced drug resistance rate, and a liver histological improvement at year 1, thereby improving the long-term treatment efficacy and the probability of treatment discontinuation in HBeAg-positive patients. Stepwise Cox regression analyses revealed that baseline IgG1-G0F >30% was an independent factor that links to virological response (HR 3.071, 95% CI 1.835-5.141, P < 0.001) or HBeAg seroconversion (HR 2.034, 95% CI 1.011-4.093, P = 0.046). Furthermore, a high IgG1-G0F level at the treatment endpoint was associated with an off-treatment sustained virological response. In conclusion, IgG1-G0F favors the medication outcome for HBeAg-positive chronic hepatitis B.

原文English
文章編號1957
期刊Scientific reports
7
發行號1
DOIs
出版狀態Published - 2017 十二月 1

指紋

Hepatitis B e Antigens
Immunoglobulin G
Hepatitis B virus
Serum
Therapeutics
Liver
Chronic Hepatitis B
Virus Diseases
Glycosylation
Drug Resistance
Antiviral Agents
Mass Spectrometry
Regression Analysis
Inflammation
DNA

All Science Journal Classification (ASJC) codes

  • General

引用此文

@article{481a4b7e5f2e459f8c9fc81bccaed667,
title = "Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG",
abstract = "Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed. After a screening of 1,085 patients, 132 eligible HBV e antigen (HBeAg)-positive and 101 HBeAg-negative patients with anti-HBV nucleos(t)ide analogue monotherapy were enrolled with on-treatment follow-ups for at least one year. IgG1 N-glycome was profiled using mass spectrometry and evaluated for its relevance in treatment responses. The results indicated that a high level of serum fucosyl-agalactosyl IgG1 (IgG1-G0F) at baseline was associated with the severity of liver inflammation and damage but advanced treatment responses, including HBV DNA loss, HBeAg seroconversion, a reduced drug resistance rate, and a liver histological improvement at year 1, thereby improving the long-term treatment efficacy and the probability of treatment discontinuation in HBeAg-positive patients. Stepwise Cox regression analyses revealed that baseline IgG1-G0F >30{\%} was an independent factor that links to virological response (HR 3.071, 95{\%} CI 1.835-5.141, P < 0.001) or HBeAg seroconversion (HR 2.034, 95{\%} CI 1.011-4.093, P = 0.046). Furthermore, a high IgG1-G0F level at the treatment endpoint was associated with an off-treatment sustained virological response. In conclusion, IgG1-G0F favors the medication outcome for HBeAg-positive chronic hepatitis B.",
author = "Ho, {Cheng Hsun} and Tsai, {Hung Wen} and Lee, {Chen Yeh} and Huang, {Li Juan} and Chien, {Rong Nan} and Wu, {I. Chin} and Chiu, {Yen Cheng} and Liu, {Wen Chun} and Cheng, {Pin Nan} and Chang, {Ting Tsung} and Chen, {Shu Hui}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-02158-5",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG

AU - Ho, Cheng Hsun

AU - Tsai, Hung Wen

AU - Lee, Chen Yeh

AU - Huang, Li Juan

AU - Chien, Rong Nan

AU - Wu, I. Chin

AU - Chiu, Yen Cheng

AU - Liu, Wen Chun

AU - Cheng, Pin Nan

AU - Chang, Ting Tsung

AU - Chen, Shu Hui

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed. After a screening of 1,085 patients, 132 eligible HBV e antigen (HBeAg)-positive and 101 HBeAg-negative patients with anti-HBV nucleos(t)ide analogue monotherapy were enrolled with on-treatment follow-ups for at least one year. IgG1 N-glycome was profiled using mass spectrometry and evaluated for its relevance in treatment responses. The results indicated that a high level of serum fucosyl-agalactosyl IgG1 (IgG1-G0F) at baseline was associated with the severity of liver inflammation and damage but advanced treatment responses, including HBV DNA loss, HBeAg seroconversion, a reduced drug resistance rate, and a liver histological improvement at year 1, thereby improving the long-term treatment efficacy and the probability of treatment discontinuation in HBeAg-positive patients. Stepwise Cox regression analyses revealed that baseline IgG1-G0F >30% was an independent factor that links to virological response (HR 3.071, 95% CI 1.835-5.141, P < 0.001) or HBeAg seroconversion (HR 2.034, 95% CI 1.011-4.093, P = 0.046). Furthermore, a high IgG1-G0F level at the treatment endpoint was associated with an off-treatment sustained virological response. In conclusion, IgG1-G0F favors the medication outcome for HBeAg-positive chronic hepatitis B.

AB - Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed. After a screening of 1,085 patients, 132 eligible HBV e antigen (HBeAg)-positive and 101 HBeAg-negative patients with anti-HBV nucleos(t)ide analogue monotherapy were enrolled with on-treatment follow-ups for at least one year. IgG1 N-glycome was profiled using mass spectrometry and evaluated for its relevance in treatment responses. The results indicated that a high level of serum fucosyl-agalactosyl IgG1 (IgG1-G0F) at baseline was associated with the severity of liver inflammation and damage but advanced treatment responses, including HBV DNA loss, HBeAg seroconversion, a reduced drug resistance rate, and a liver histological improvement at year 1, thereby improving the long-term treatment efficacy and the probability of treatment discontinuation in HBeAg-positive patients. Stepwise Cox regression analyses revealed that baseline IgG1-G0F >30% was an independent factor that links to virological response (HR 3.071, 95% CI 1.835-5.141, P < 0.001) or HBeAg seroconversion (HR 2.034, 95% CI 1.011-4.093, P = 0.046). Furthermore, a high IgG1-G0F level at the treatment endpoint was associated with an off-treatment sustained virological response. In conclusion, IgG1-G0F favors the medication outcome for HBeAg-positive chronic hepatitis B.

UR - http://www.scopus.com/inward/record.url?scp=85019417651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019417651&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-02158-5

DO - 10.1038/s41598-017-02158-5

M3 - Article

C2 - 28512353

AN - SCOPUS:85019417651

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 1957

ER -